Atlas Trials

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression

Clinical trial NCT03965858 · COMPLETED

Trial details

NCT number
NCT03965858
Sponsor
Celon Pharma SA
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Major Depressive Disorder
Start date
2019-02-25
Primary completion
2020-03-15
Enrollment
88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.